YPrime has acquired software development company Tryl to expand its expertise to support decentralised clinical trials.
Tryl’s patient engagement solution combines personalisation and applied behavioural science to increase engagement, cut down dropouts, and provide results in clinical trials.
With the Tryl takeover, YPrime will gain access to all the development expertise, staff and intellectual properties and will merge with Patient Engagement Technologies solutions of the latter.
The tools of Tryl offer a tailored, predictive and relative experience to the complete journey of the patient.
Furthermore, its engagement score could lower the rate of patient dropouts.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
YPrime CEO Shawn Blackburn said: “YPrime’s major priority has always been to anticipate the needs of tomorrow’s clinical trials and create powerful eClinical tools that simplify the lives of sponsors, sites, and patients.
“This combination with Tryl helps us leap ahead in fulfilling our vision of creating the industry’s first-of-its-kind solution to help keep patients more informed and engaged throughout the entire clinical trial process, especially as our industry accelerates toward decentralised clinical trial models.”
The Tryl team uses established behavioural principles from other industries such as professional sports and consumer finance to boost patient adherence to trial protocols.
Its predictive analytics aid clinicians to intervene before the dropout of the study subjects. This method lowers the burden of participants while also increasing value for sponsors as well as researchers.
Tryl CEO Ian Greenfield said: “An ever-increasing focus on patient centricity demands an integrated approach to how patients are engaged.
“YPrime has a strong vision for the future and by bringing together offerings from our two companies, we can create a novel solution that takes head on the most pressing challenges associated with attracting, engaging, and retaining patients.”
